Core Viewpoint - The company, Far East Pharmaceutical (00512.HK), has received a drug registration certificate from the National Medical Products Administration for its innovative global drug Ryaltris, a compound nasal spray for treating allergic rhinitis in adults and children, achieving approval without any supplementary information requests during the review process [1] Group 1 - The drug Ryaltris is specifically indicated for the treatment of allergic rhinitis (AR) in both adults and children [1] - The approval process for Ryaltris was completed without any requests for additional documentation, indicating a smooth regulatory review [1] - The receipt of the drug registration certificate marks a significant milestone for the company in its product development and market entry strategy [1]
远大医药全球创新复方鼻喷剂国内获批